Information  X 
Enter a valid email address

RTW Venture Fund Ltd (RTW)

  Print      Mail a friend

Wednesday 01 April, 2020

RTW Venture Fund Ltd

Series B2 Financing in iTeos Therapeutics

RNS Number : 4864I
RTW Venture Fund Limited
01 April 2020
 

LEI: 549300Q7EXQQH6KF7Z84

01   April 2020

RTW Venture Fund Limited

RTW Participates in Series B2 Financing Round in iTeos Therapeutics

RTW Venture Fund Limited (the "Company") notes the announcement by iTeos Therapeutics, Inc. ("iTeos"), a privately-held clinical-stage biotechnology company developing innovative cancer immunotherapies, of its completion of a $125 million Series B2 financing.

The Company alongside RTW Investments, LP (the "Investment Manager") participated in the financing round together with other investment firms.

"We are excited to support iTeos' effort to develop novel immunotherapies for cancer patients. TIGIT is an exciting novel immune checkpoint target, and we believe EOS884448 has potential to be a leading therapeutic in the class."   said Roderick T. Wong, MD, managing partner of the Investment Manager.

The announcement can be accessed on iTeos' website at: www.iteostherapeutics.com and full text of the announcement from iTeos is contained below. 

 

For Further Information

RTW Investments, LP   +1 (646) 343 9280
Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Business Development Associate

 

Brunswick     +44 (0)20 7404 5959
Charis Gresser

Ayesha Bharmal

 

 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

 

 

 

 

 

 

 

 

iTeos Therapeutics Closes $125 Million Series B2 Financing

 

-  Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint

-  Oversubscribed round co-led by new investors RA Capital Management and Boxer Capital

-  New investors Janus Henderson Investors, RTW Investments and Invus also participated along with previous Series B investors including MPM Capital and HBM Partners

 

Cambridge, MA and Gosselies, Belgium - April 1, 2020 - iTeos Therapeutics Inc. , a privately-held clinical-stage biotechnology company developing innovative cancer immunotherapies, announced today the closing of an oversubscribed Series B2 financing, which raised a total of $125 million.

 

The Series B2 financing round was co-led by RA Capital Management and Boxer Capital, and included new investors Janus Henderson Investors, RTW Investments and Invus along with existing investors MPM Capital, HBM Partners, 6 Dimensions Capital, Curative Ventures, Fund+, VIVES Louvain Technology Fund, SRIW, and SFPI.

 

Proceeds from the financing will support the Company's continued growth and advance the clinical development of its two lead product candidates, EOS-850, a best-in-class adenosine A2A receptor antagonist and EOS-448, an ADCC-enabled anti-TIGIT antibody. EOS-850 is currently being evaluated in a Phase 1/2 clinical trial both as a single agent and in combination in several solid tumor indications. The Company plans to initiate dosing for the combination cohorts for this trial in the second quarter of 2020. The Company also recently initiated the Phase 1 portion of a Phase 1/2 clinical study of EOS-448, currently being evaluated in patients with solid tumors and hematological malignancies. Proceeds from this financing will also support the advancement of additional first-in-class preclinical programs targeting the adenosine pathway and Tregs.

 

"We are very pleased to have the strong support of this leading class of investors who share our excitement for the highly innovative oncology therapies we have developed at iTeos," said Michel Detheux, PhD, President and Chief Executive Officer at iTeos. "We look forward to accelerating and expanding our clinical development efforts to identify the most promising indications and combinations for people suffering with cancer. This financing maximizes our ability to execute our development plans alone or in partnership."

 

 " iTeos' pipeline of best-in-class agents has the potential to usher in a new wave of immuno-oncology therapeutics and the Company is well-positioned to make a significant, positive impact in the treatment of patients with a wide variety of cancer types," commented Derek DiRocco, Principal, RA Capital Management. "We are thrilled to collaborate with this experienced group of high-quality investors and partner with the iTeos management team as they continue to innovate and progress these exciting programs through clinical development."

 

"The iTeos team has done a remarkable job developing a pipeline of differentiated, potentially best-in-class cancer therapies," said Aaron Davis, Co-Founder and Chief Executive Officer, Boxer Capital of the Tavistock Group. "We are pleased to be joining them as they continue to execute and implement their vision for transforming the cancer treatment landscape."

 

Derek DiRocco and Aaron Davis will join the iTeos Board as Non-Executive Directors.

 

 

About iTeos Therapeutics

iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of people living with cancer by designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs). The Company's lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2 study. Its second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), entered the clinic in February 2020. iTeos Therapeutics is headquartered in Cambridge, MA with a world-class research center in Gosselies, Belgium. For more information, please visit www.iteostherapeutics.com .

 

About RA Capital Management

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization. For more information, please visit https://www.racap.com .

 

About Boxer Capital, LLC

Boxer Capital, LLC is a private biotechnology investment fund based in San Diego, California that invents and invests in drug development across multiple therapeutic indications. Founded by the life sciences team at Tavistock Group in 2005, Boxer Capital maintains a concentrated portfolio of public and private companies. For more information, please visit www.boxercap.com .

 

For further information, please contact:

Michel Detheux, CEO

iTeos Therapeutics SA

[email protected]  

 

Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji

Consilium Strategic Communications

+44 203 709 5700

[email protected]

Sarah McCabe and Zofia Mita

Stern Investor Relations, Inc.

+ 1 212 362 1200

[email protected]

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
STRUARNRRUUSRAR

a d v e r t i s e m e n t